Liquid biopsy is a hot topic in the field of precision medicine for cancer detection, diagnosis and prognosis. The most popular liquid biopsy sample is circulating DNA, which can be mostly used for cancer prognosis and therapeutic management. Alongside DNAs and other molecules, circulating miRNAs have been attracting attention as candidate biomarkers for cancer detection and predictive prognosis. However, the specific features of circulating miRNAs are still under investigation, and factors such as sample handling methods and control selection can impact the results of circulating miRNA analyses. Oncoliq emerged as a spin-off from CONICET with the mission to decrease cancer mortality by early detection. In this talk I will present our first product already developed: Oncoliq breast, based on miRNA liquid biopsy for breast cancer detection. After biomarker discovery and analytic validation we applied machine learning to generate algorithms that can classify breast cancer and non-cancer patients. Oncoliq breast test is highly specific and sensitive for early cancer detection (Stage 0 and 1), and it will be an incomparable tool for the follow up of patients with dense breast and/or Bi Rad 3.